Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer
We concluded that XELOX + DC-CIK immunotherapy for postsurgical CRC patients offers reduced rates of treatment-induced adverse events, extended 2-year DFS, enhanced immunity, and increased physiological antitumor responses.
Authors
- Tong Jiang (ORCID: https://orcid.org/0000-0002-1446-8080)
- Yinuo Wang (ORCID: https://orcid.org/0000-0001-5515-9519)
- Huiying Yu (ORCID: https://orcid.org/0000-0002-8703-9754)
- Zhendong Zheng (ORCID: https://orcid.org/0000-0003-1124-082X)
- Juan Chen (ORCID: https://orcid.org/0000-0002-8006-0630)
- Zhenyu Ding (ORCID: https://orcid.org/0000-0003-1497-5485)
- Ying Piao
Institutions
- Shenyang Pharmaceutical University (CN)
- Shenyang Center for Disease Control and Prevention (CN)
- General Hospital of Shenyang Military Region (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Surgery
- Published
- 2024-09-27
- DOI
- https://doi.org/10.4240/wjgs.v16.i10.3202
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Liaoning Province